|
Name |
tardioxopiperazine B
|
Molecular Formula | C24H31N3O2 | |
IUPAC Name* |
(3S,6S)-3-methyl-6-[[2-(2-methylbut-3-en-2-yl)-7-(3-methylbut-2-enyl)-1H-indol-3-yl]methyl]piperazine-2,5-dione
|
|
SMILES |
C[C@H]1C(=O)N[C@H](C(=O)N1)CC2=C(NC3=C(C=CC=C23)CC=C(C)C)C(C)(C)C=C
|
|
InChI |
InChI=1S/C24H31N3O2/c1-7-24(5,6)21-18(13-19-23(29)25-15(4)22(28)26-19)17-10-8-9-16(20(17)27-21)12-11-14(2)3/h7-11,15,19,27H,1,12-13H2,2-6H3,(H,25,29)(H,26,28)/t15-,19-/m0/s1
|
|
InChIKey |
QNQMVKRHUCFRIY-KXBFYZLASA-N
|
|
Synonyms |
tardioxopiperazine B; CHEMBL249257; CHEBI:193006; cyclo-L-2-tert-DMA-7-DMA-Trp-L-Ala; 2-(1,1-Dimethyl-2-propenyl)-7-isopentenylcyclo(L-Trp-L-Ala-)
|
|
CAS | NA | |
PubChem CID | 10810597 | |
ChEMBL ID | CHEMBL249257 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 393.5 | ALogp: | 5.1 |
HBD: | 3 | HBA: | 2 |
Rotatable Bonds: | 6 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 74.0 | Aromatic Rings: | 3 |
Heavy Atoms: | 29 | QED Weighted: | 0.637 |
Caco-2 Permeability: | -4.848 | MDCK Permeability: | 0.00001320 |
Pgp-inhibitor: | 0.981 | Pgp-substrate: | 0.05 |
Human Intestinal Absorption (HIA): | 0.037 | 20% Bioavailability (F20%): | 0.91 |
30% Bioavailability (F30%): | 0.095 |
Blood-Brain-Barrier Penetration (BBB): | 0.771 | Plasma Protein Binding (PPB): | 93.29% |
Volume Distribution (VD): | 0.962 | Fu: | 3.47% |
CYP1A2-inhibitor: | 0.301 | CYP1A2-substrate: | 0.316 |
CYP2C19-inhibitor: | 0.909 | CYP2C19-substrate: | 0.123 |
CYP2C9-inhibitor: | 0.719 | CYP2C9-substrate: | 0.557 |
CYP2D6-inhibitor: | 0.749 | CYP2D6-substrate: | 0.648 |
CYP3A4-inhibitor: | 0.944 | CYP3A4-substrate: | 0.501 |
Clearance (CL): | 1.813 | Half-life (T1/2): | 0.164 |
hERG Blockers: | 0.056 | Human Hepatotoxicity (H-HT): | 0.505 |
Drug-inuced Liver Injury (DILI): | 0.838 | AMES Toxicity: | 0.013 |
Rat Oral Acute Toxicity: | 0.913 | Maximum Recommended Daily Dose: | 0.267 |
Skin Sensitization: | 0.113 | Carcinogencity: | 0.078 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.009 |
Respiratory Toxicity: | 0.979 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC002068 | 0.756 | D0N1WU | 0.232 | ||||
ENC000859 | 0.693 | D0O6KE | 0.220 | ||||
ENC003867 | 0.673 | D0W7WC | 0.217 | ||||
ENC003866 | 0.673 | D01AYJ | 0.216 | ||||
ENC002460 | 0.663 | D0Q0PR | 0.215 | ||||
ENC002631 | 0.648 | D0B4DC | 0.205 | ||||
ENC001987 | 0.640 | D0W6DG | 0.202 | ||||
ENC002896 | 0.596 | D0NG7O | 0.198 | ||||
ENC003796 | 0.573 | D0H5MB | 0.197 | ||||
ENC002630 | 0.505 | D0WN0U | 0.197 |